V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Vericel Executive Compensation (FY25)

VCEL · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 1, 2026
288 figures on this page: 277 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Dominick Colangelo, President and Chief Executive Officer, received $11,156,368 in total compensation for fiscal 2025, and Colangelo's total moved 9.0% higher from the $10,237,525 reported for fiscal 2024; the company reported a chief executive pay ratio of 40:1 for fiscal 2025, against median employee compensation of $276,377. Meanwhile, shareholders supported the say-on-pay proposal with 78.9% of votes cast for or against in favor at the meeting held April 29, 2026 for fiscal 2025. The disclosed peer group includes Alphatec Holdings, Inc., Amicus Therapeutics, Inc., Artivion, Inc., AtriCure, Inc. and Beam Therapeutics, Inc., among others.
Chief executive, fiscal 2025
◇
Dominick Colangelo
Latest say-on-pay support
=
April 29, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Dominick Colangelo: $10,237,525 → $11,156,368 (9.0% higher)
CEO pay ratio: 41:1 → 40:1 (2.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Vericel's chief executive and what were they paid?
Dominick Colangelo, President and Chief Executive Officer, received $11,156,368 in total compensation for fiscal 2025. Colangelo's total moved 9.0% higher from the $10,237,525 reported for fiscal 2024.
What was Vericel's say-on-pay result?
Shareholders supported the say-on-pay proposal with 78.9% of votes cast for or against in favor at the meeting held April 29, 2026 for fiscal 2025.
Which companies are in Vericel's peer group?
The disclosed peer group includes Alphatec Holdings, Inc., Amicus Therapeutics, Inc., Artivion, Inc., AtriCure, Inc. and Beam Therapeutics, Inc., among others.
What is Vericel's chief executive pay ratio?
The company reported a chief executive pay ratio of 40:1 for fiscal 2025, against median employee compensation of $276,377.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dominick Colangelo
President and CEO
◇—◇◇◇—◇◇
Michael Halpin
Chief Operating Officer
◇—◇◇◇—◇◇
Joe Mara
Chief Financial Officer
◇—◇◇◇—◇◇
Jonathan Hopper
Chief Medical Officer
◇—◇◇◇—◇◇
Sean Flynn
Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dominick Colangelo
President and CEO
◇—◇◇◇—◇◇
Michael Halpin
Chief Operating Officer
◇—◇◇◇—◇◇
Joe Mara
Chief Financial Officer
◇—◇◇◇—◇◇
Jonathan Hopper
Chief Medical Officer
◇—◇◇◇—◇◇
Sean Flynn
Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dominick Colangelo
President and Chief Executive Officer
◇—◇◇◇—◇◇
Michael Halpin
Chief Operating Officer
◇—◇◇◇—◇◇
Joe Mara
Chief Financial Officer
◇—◇◇◇—◇◇
Jonathan Hopper
Chief Medical Officer
◇—◇◇◇—◇◇
Sean Flynn
Chief Legal Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Dominick ColangeloOPTION◇——◇—◇◇
Dominick ColangeloRSU◇——◇——◇
Joe MaraRSU◇——◇——◇
Joe MaraOPTION◇——◇—◇◇
Jonathan HopperRSU◇——◇——◇
Jonathan HopperOPTION◇——◇—◇◇
Michael HalpinOPTION◇——◇—◇◇
Michael HalpinRSU◇——◇——◇
Sean FlynnRSU◇——◇——◇
Sean FlynnOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Sean FlynnOption◇—◇2/20/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/17/2033
Option◇—◇2/18/2032
Option◇—◇2/22/2034
RSU◇◇——
Dominick ColangeloOption◇—◇2/18/2032
RSU◇◇——
RSU◇◇——
Option◇—◇2/20/2035
Option◇—◇2/17/2033
Option◇—◇2/22/2034
RSU◇◇——
RSU◇◇——
Michael HalpinOption◇—◇2/17/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/20/2035
Option◇—◇2/18/2032
Option◇—◇2/22/2034
Jonathan HopperRSU◇◇——
RSU◇◇——
Option◇—◇2/20/2035
Option◇—◇2/17/2033
RSU◇◇——
Option◇—◇2/18/2032
Option◇—◇2/22/2034
RSU◇◇——
Joe MaraRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/17/2033
Option◇—◇2/18/2032
Option◇—◇2/22/2034
Option◇—◇2/20/2035
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert L. Zerbe
Board chair
◇◇◇———◇
Alan L. Rubino
◇◇◇———◇
Kevin F. McLaughlin
◇◇◇———◇
Heidi Hagen
◇◇◇———◇
Paul K. Wotton
◇◇◇———◇
Lisa Wright
◇◇◇———◇
Steven C. Gilman
◇—————◇
Dominick Colangelo served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alphatec Holdings, Inc. ATEC
  • Amicus Therapeutics, Inc. FOLD
  • Artivion, Inc. AORT
  • AtriCure, Inc. ATRC
  • Beam Therapeutics, Inc. BEAM
  • Corcept Therapeutics, Inc. CORT
  • Glaukos Corporation GKOS
  • Inari Medical, Inc. NARI
  • iRhythm Holdings, Inc. IRTC
  • Ironwood Pharmaceuticals, Inc. IRWD
  • PROCEPT BioRobotics Corporation PRCT
  • PTC Therapeutics, Inc. PTCT
  • Rhythm Pharmaceuticals, Inc. RYTM
  • RxSight, Inc. RXST
  • STAAR Surgical Company STAA
  • Supernus Pharmaceuticals, Inc. SUPN
  • Tandem Diabetes Care, Inc. TNDM
  • TransMedics Group, Inc. TMDX
  • Travere Therapeutics, Inc. TVTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 29, 2026=◇◇◇
2024April 30, 2025=◇◇◇
2023May 1, 2024=◇◇◇
2022May 3, 2023=◇◇◇
2021April 27, 2022=◇◇◇
2020April 28, 2021=◇◇◇
2019April 29, 2020=◇◇◇
2018May 1, 2019=◇◇◇
2017May 2, 2018=◇◇◇
2016May 3, 2017=◇◇◇
2015May 4, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Vericel files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Vericel disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Vericel sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Vericel's disclosed peer group is defensible, who names Vericel back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
288 figures on this page: 277 cited to the filing that reported them, 11 calculated from figures it prints.
277 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001140361-26-018538
  2. 0001308179-26-000094
    CEO Pay Ratio · Compensation of Directors · Executive Compensation Tables · Grants of Plan-Based Awards · and 2 more sections
  3. 0001140361-25-017110
  4. 0001308179-25-000169
    Summary Compensation Table
  5. 0001140361-24-024327
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001308179-24-000206
    Summary Compensation Table
  7. 0001140361-23-023201
  8. 0001104659-22-053666
  9. 0001104659-21-057713
  10. 0001104659-20-055469
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001104659-19-026009
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001104659-18-030322
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001104659-17-030325
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001104659-16-118755
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Vericel executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/VCEL (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Vericel and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Vericel discloses

The companies named in VCEL's own disclosed peer group.

Amicus Therapeutics, Inc.Artivion, Inc.AtriCure, Inc.Beam Therapeutics, Inc.Glaukos CorporationiRhythm Holdings, Inc.Ironwood Pharmaceuticals, Inc.PTC Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.RxSight, Inc.STAAR Surgical CompanySupernus Pharmaceuticals, Inc.Tandem Diabetes Care, Inc.Travere Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy